GlassScriptPhysician profile
Amy L Davis
NPI 1417214909
$2,547.45
in general payments reported to CMS, 2019-2025
50 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $384 · 2024: $726 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,547.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $281.74 | 2023-2024 | Evoke Scs, Evoke |
| Abbott Laboratories | $253.29 | 2024 | Proclaim, Eterna |
| Merck Sharp & Dohme LLC | $177.56 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $119.27 | 2025 | Lynparza, Enhertu |
| Sobi, INC | $96.86 | 2024-2025 | |
| Curonix LLC | $90.81 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Daiichi Sankyo INC. | $81.39 | 2024-2025 | Enhertu |
| Pharmaessentia USA Corporation | $80.51 | 2025 | Besremi |
| Lilly USA, LLC | $74.67 | 2025 | Jaypirca, Verzenio |
| Genentech USA, INC. | $68.00 | 2025 | Polivy, Itovebi, Venclexta |
| Glaxosmithkline, LLC. | $60.99 | 2024-2025 | Ojjaara, Blenrep |
| Ipsen Biopharmaceuticals, INC | $58.98 | 2025 | Onivyde |
| Iovance Biotherapeutics, INC. | $58.31 | 2025 | Amtagvi |
| Averitas Pharma INC. | $56.10 | 2023-2024 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $52.00 | 2024-2025 | Ninlaro, Fruzaqla |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $49.33 | 2025 | Vyloy |
| Beone Medicines USA, INC. | $47.91 | 2025 | Tevimbra |
| Relievant Medsystems, INC. | $46.66 | 2023 | Intracept |
| Novartis Pharmaceuticals Corporation | $43.38 | 2025 | |
| Scilex Pharmaceuticals INC. | $42.85 | 2023-2024 | Ztlido |
| Spr Therapeutics, INC | $38.17 | 2023-2024 | Sprint Pns System |
| Genzyme Corporation | $35.58 | 2025 | |
| Jazz Pharmaceuticals INC. | $35.35 | 2025 | |
| Medtronic, INC. | $33.24 | 2023 | Intellis Adaptivestim |
| Nalu Medical, INC. | $33.10 | 2024 | Nalu Neurostimulation System |
| Beigene USA, INC. | $31.64 | 2025 | Tevimbra |
| Painteq LLC | $31.58 | 2024 | Painteq |
| Eisai INC. | $29.51 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.25 | 2025 | |
| Karyopharm Therapeutics INC. | $27.61 | 2025 | Xpovio |
| Exelixis INC. | $26.39 | 2025 | Cabometyx |
| Kite Pharma, INC. | $24.63 | 2025 | Yescarta |
| Pfizer INC. | $24.50 | 2025 | |
| Avanos Medical | $23.34 | 2023 | Genvisc 850 Sodium Hyaluronate |
| Rigel Pharmaceuticals, INC. | $22.47 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Regeneron Healthcare Solutions, INC. | $20.74 | 2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $20.23 | 2025 | |
| Collegium Pharmaceutical, INC. | $20.03 | 2024 | Belbuca |
| Servier Pharmaceuticals LLC | $19.56 | 2025 | |
| Syndax Pharmaceuticals, INC. | $19.42 | 2025 | |
| Deciphera Pharmaceuticals INC. | $19.00 | 2025 | Qinlock |
| Alexion Pharmaceuticals, INC. | $18.30 | 2025 | Ultomiris |
| Spinal Simplicity, LLC | $17.95 | 2023 | Ha Minuteman G3-R |
| Incyte Corporation | $16.30 | 2025 | Jakafi |
| Mml US, INC. | $15.81 | 2023 | Reactiv8 |
| Kowa Pharmaceuticals America, INC. | $15.16 | 2023 | Seglentis |
| Merz Pharmaceuticals, LLC | $14.96 | 2024 | Xeomin |
| Apellis Pharmaceuticals, INC. | $14.87 | 2025 | Empaveli |
| Emd Serono, INC. | $14.47 | 2025 | |
| Agios Pharmaceuticals, INC. | $13.68 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.